ArticleVirusdisease2025
MiR-155 and MiR-1275 relation with graft-versus-host disease and hepatitis B in hematopoietic stem cell transplant recipients.
Article in Virusdisease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dysregulated Expression of miR-222 and miR-15a in Transfusion-Dependent Thalassemia: Associations with Torque Teno Virus and Cytomegalovirus Infections.International journal of hematology-oncology and stem cell research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: MicroRNAs (miRNAs) play many roles in basic biological processes such as virus proliferation and growth. In this research, we sought to investigate the prognostic and diagnostic potential of miR-155 and miR-1275 in the induction and severity of Graft-Versus-Host Disease (aGVHD) following hematopoietic stem cell transplantation (HSCT). Additionally, we evaluated the association between these miRNAs' expression and HBV infection in patients with HSCT. Method: In the present research, 135 consecutive patients receiving allogeneic HSCT were enrolled. We assessed the expression levels of miR-155 and miR-1275 in the peripheral blood of patients before and after HSCT by SYBR Green Real-Time PCR. In these patients Hepatitis B virus (HBV) load was also determined by HBV antibody assay. Results: MiR-1275 and miR-155 expression levels were significantly lower in patients after HSCT. A significant association was found between miR-155 and miR-1275 expression levels in patients who developed aGvHD compared with those without aGvHD. We also found that only MiR-155 expression level was significantly increased in HBV + patients compared with HBV- patients. Conclusion: Both MiR-1275 and miR-155 genes have the potential to be used as therapeutic targets in HSCT patients in the future. The expression level of both could be employed as biomarkers for aGvHD induction. Moreover, MiR-155 expression level was connected to the pathogenesis of HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.